Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12425MR)

This product GTTS-WQ12425MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12425MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5451MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ12133MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ4827MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ13563MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ13517MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ14821MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ14292MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ12942MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW